Our Science
Novel Dual‐acting Glucokinase Activator (GKA) Dorzagliatin (HMS5552) Achieved Primary Efficacy Endpoint with Good Safety Profiles in T2DM Patients Results of 24 Week Treatment in a Phase III Monotherapy Trial (SEED Study)
2020 ADA Poster
Online link unavailable, presentation available upon request. (BD@ksxianqing.com)
Focus Us
Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: （沪）-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x